Results showed that TP53, TGF-beta, MYC, NRF2, WNT, and RTK-RAS signaling pathways were enriched in the 171 patients who had received adjuvant therapy for gastric cancer (Figure 4D). This evidence concerns the gene MYC and gastric cancer.